HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $27.
October 10, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Enanta Pharma, maintaining a price target of $27. This suggests confidence in the company's potential for growth.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst firm like HC Wainwright & Co. indicates a positive outlook for Enanta Pharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100